AstraZeneca COVID-19 vaccine study put on hold due to suspected adverse reaction in UK participant
Pharmaceutical company AstraZeneca will put an experimental coronavirus vaccine study on hold in the U.S. after a participant in Britain faced an apparent serious adverse reaction, according to a report.
Pharmaceutical company AstraZeneca will put an experimental coronavirus vaccine study on hold in the U.S. after a participant in Britain faced an apparent serious adverse reaction, according to a report.
The Anglo-Swedish company’s “standard review process triggered a pause to vaccination to allow review of safety data,” an AstraZeneca spokesperson said.
The pause is “a routine action which has to happen whenever there is a potentially unexplained illness in one of the trials, while it is investigated, ensuring we maintain the integrity of the trials.”
The pause is “a routine action which has to happen whenever there is a potentially unexplained illness in one of the trials, while it is investigated, ensuring we maintain the integrity of the trials.”
AstraZeneca is “working to expedite the review of the single event to minimize any potential impact on the trial timeline.”
A suspected serious adverse reaction includes symptoms that require hospitalization, life-threatening illness and even death. It’s suspected the adverse reaction happened in the Phase 2/3 trial underway in Britain. CLICK HERE FOR MORE.
In other developments:
- Trump claims coronavirus vaccine might be delivered soon: 'You could have a very big surprise coming up'
- Newt Gingrich: Search for coronavirus vaccine is making important progress
- Pfizer-BioNTech potential coronavirus vaccine shows promise in additional data
In other developments:
- Trump claims coronavirus vaccine might be delivered soon: 'You could have a very big surprise coming up'
- Newt Gingrich: Search for coronavirus vaccine is making important progress
- Pfizer-BioNTech potential coronavirus vaccine shows promise in additional data
No hay comentarios:
Publicar un comentario